Pharmaceutical concern

Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany.

Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert in 1950 and headquartered in Irvine, CA.

Foshan Boehringer Medical Equipment Co., Ltd., established on 2014-02-28, The business scope includes holding valid approval certificates to engage in the second,Three types of medical device business,food circulation;Sales:contact lenses(soft,rigid,air permeability,Orthokeratology Contact Lenses)and care solutions;wholesale,retail:Class I medical device,electronic product,computer software,Glasses and Accessories,Wujinjiaodian,Mechanical and electrical equipment products,Equipment;Domestic Trade;Development of medical device technology,Technical consulting and technology transfer;Biological Technology,Technology development in the field of medical science and technology,technology transfer,technical consulting,Technical Services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Tianjin Linda Biotechnology Co., Ltd., established on 2010-05-19, The business scope includes biogenetic drugs,Vaccine Technology Development,Transfer and technical services;biological reagent,skin care products,Technical development and sales of health products.The country has a franchise,The special provisions shall be handled according to the special provisions of the franchise.

Menicon creates contact lenses. In response to consumer demand, they increase the range of products and services available. Animal ophthalmic care uses the same technology that was developed for contact lenses for people. They aid in the growth of veterinary ophthalmology in cooperation with veterinarians. Use the technology that has been developed for the creation of care and contact lenses in the environmental business sector.

Hangzhou Chaoxi Medical Technology Co., Ltd., established on 2020-09-01, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Medical equipment rental;Information Technology Consulting Services;Sales of power electronic components;Office Supplies Sales;Retailing of computer software, hardware and auxiliary equipment;General merchandise sales(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:Class III medical device business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).

Hainan Shiboli Biotechnology Co., Ltd., established on 2015-09-10, Business scope includes medicinal planting,cosmetic,Health products,food,Research and development of agricultural and sideline products,Production,Sales,Homestay service,Homestay project development,manage,Import and export trade of goods and technology,information Technology,Technology development of electronic products,Technical Services,technical consulting,Technical Training,technology transfer,Cultural activities planning,Exhibition planning.(General operating items self-management,Licensed business projects are operated with relevant licenses or approval documents)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Tianjin Puying Biotechnology Co., Ltd., established on 2004-04-13, The business scope includes biogenetic drugs,vaccine,cosmetic,Technology development of health products,transfer;cosmetic,Skin care sales;Bioreagent technology development,Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Beijing Meifuyuan Biomedical Technology Co., Ltd., established on 2009-02-27, Business scope includes technology development,technology transfer,technical consulting,Technology Promotion,Technical Services.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Nanjing Daoda Pharmaceutical Co., Ltd., established on 2013-10-11, The scope of business includes two types of6826Other physical therapy and rehabilitation equipment,6864Production of other medical hygiene materials and dressings;biomedicine,Research and development of medical device products;Iclass of medical devices,disinfectant,Research and development of hygiene products,Production,Sales;Sales of Class II Medical Devices.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Liaoning Meizilin Pharmaceutical Co., Ltd., established on 2002-06-14, Business scope includes licensed projects:Production of Class II Medical Devices,Production of Class III Medical Devices,Class III medical device business,Cosmetic production,Production of hygiene products and single-use medical products,Disinfectant production(Free of Hazardous Chemicals),pharmaceutical production,Drug Wholesale,Technology Import and Export,Import and export(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Production of Class I Medical Devices,Sales of Class I Medical Devices,Sales of Class II Medical Devices,Cosmetics Wholesale,Cosmetics Retail,Sales of hygiene products and single-use medical products,Disinfectant sales(Free of Hazardous Chemicals),Manufacture of technical textile products,Sales of industrial textile products,Production of labor protection products,Sales of labor protection products,Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion,internet sales(Except for products that require a license for sale),Information Technology Consulting Services,Chemical product sales(No licensed chemical products),Chemical product production(No licensed chemical products)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

FortuneRock (China) Ltd., a privately held biotechnology and biopharmaceutical company registered in Beijing. Along with its 3 wholly owned subsidiaries, Tianjin SinoBiotech Ltd., SinoBiotech (Tianjin) Ltd. and Beijing Bio-Fortune Ltd., the group is focused on the discovery, development, and commercialization of novel, patent-protected gene-based recombinant protein drugs with high clinical value for the treatment of life-threatening and debilitating diseases. Currently, the company has one drug in clinical Phase I, one in clinical Phase II, another waiting for approval to enter into clinical Phase I, and several novel drugs in pre-clinical studies, all for different indications.